Trial Outcomes & Findings for Study of HPN424 in Patients With Advanced Prostate Cancer (NCT NCT03577028)
NCT ID: NCT03577028
Last Updated: 2024-02-14
Results Overview
Assess safety and tolerability at increasing dose levels of HPN424 in successive cohorts of patients with metastatic castrate resistant prostate cancer (mCRPC) to estimate the maximum tolerated dose (MTD). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
104 participants
Primary outcome timeframe
21 days
Results posted on
2024-02-14
Participant Flow
Participant milestones
| Measure |
Fixed IV
Fixed dose IV cohorts (1.3 to 150 ng/kg). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
1 Prime Step IV 36 ng/kg Target
Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
1 Prime Step IV 225-300 ng/kg Target
Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
2 Prime Step IV 300 ng/kg Target
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
2 Prime Step IV 450 ng/kg Target
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
Fixed SC
Fixed subcutaneous dose 120 ng/kg. The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
64
|
6
|
12
|
10
|
9
|
3
|
|
Overall Study
COMPLETED
|
64
|
6
|
12
|
10
|
9
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study of HPN424 in Patients With Advanced Prostate Cancer
Baseline characteristics by cohort
| Measure |
Fixed IV
n=64 Participants
Fixed dose IV cohorts (1.3 to 150 ng/kg)
|
1 Prime Step IV 36 ng/kg Target
n=6 Participants
Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg)
|
1 Prime Step IV 225-300 ng/kg Target
n=12 Participants
Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
|
2 Prime Step IV 300 ng/kg Target
n=10 Participants
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
|
2 Prime Step IV 450 ng/kg Target
n=9 Participants
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
|
Fixed SC
n=3 Participants
Fixed subcutaneous dose 120 ng/kg
|
Total
n=104 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
6 Participants
n=35 Participants
|
3 Participants
n=31 Participants
|
2 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
25 Participants
n=147 Participants
|
|
Age, Categorical
>=65 years
|
50 Participants
n=39 Participants
|
6 Participants
n=41 Participants
|
6 Participants
n=35 Participants
|
7 Participants
n=31 Participants
|
7 Participants
n=146 Participants
|
3 Participants
n=19 Participants
|
79 Participants
n=147 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
|
Sex: Female, Male
Male
|
64 Participants
n=39 Participants
|
6 Participants
n=41 Participants
|
12 Participants
n=35 Participants
|
10 Participants
n=31 Participants
|
9 Participants
n=146 Participants
|
3 Participants
n=19 Participants
|
104 Participants
n=147 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
3 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
4 Participants
n=147 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
55 Participants
n=39 Participants
|
6 Participants
n=41 Participants
|
10 Participants
n=35 Participants
|
10 Participants
n=31 Participants
|
7 Participants
n=146 Participants
|
3 Participants
n=19 Participants
|
91 Participants
n=147 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
6 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
2 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
9 Participants
n=147 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
2 Participants
n=147 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
2 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
2 Participants
n=147 Participants
|
|
Race (NIH/OMB)
Black or African American
|
6 Participants
n=39 Participants
|
2 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
9 Participants
n=147 Participants
|
|
Race (NIH/OMB)
White
|
49 Participants
n=39 Participants
|
4 Participants
n=41 Participants
|
9 Participants
n=35 Participants
|
10 Participants
n=31 Participants
|
9 Participants
n=146 Participants
|
3 Participants
n=19 Participants
|
84 Participants
n=147 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
5 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
2 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
7 Participants
n=147 Participants
|
|
Region of Enrollment
United States
|
56 participants
n=39 Participants
|
6 participants
n=41 Participants
|
11 participants
n=35 Participants
|
9 participants
n=31 Participants
|
6 participants
n=146 Participants
|
3 participants
n=19 Participants
|
91 participants
n=147 Participants
|
|
Region of Enrollment
United Kingdom
|
8 participants
n=39 Participants
|
0 participants
n=41 Participants
|
1 participants
n=35 Participants
|
1 participants
n=31 Participants
|
3 participants
n=146 Participants
|
0 participants
n=19 Participants
|
13 participants
n=147 Participants
|
PRIMARY outcome
Timeframe: 21 daysPopulation: Safety population receiving at least one dose. The study was terminated early, and therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed.
Assess safety and tolerability at increasing dose levels of HPN424 in successive cohorts of patients with metastatic castrate resistant prostate cancer (mCRPC) to estimate the maximum tolerated dose (MTD). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
Outcome measures
| Measure |
Fixed IV
n=64 Participants
Fixed dose IV cohorts (1.3 to 150 ng/kg)
|
1 Prime Step IV 36 ng/kg Target
n=6 Participants
Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg)
|
1 Prime Step IV 225-300 ng/kg Target
n=12 Participants
Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
|
2 Prime Step IV 300 ng/kg Target
n=10 Participants
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
|
2 Prime Step IV 450 ng/kg Target
n=9 Participants
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
|
Fixed SC
n=3 Participants
Fixed subcutaneous dose 120 ng/kg
|
|---|---|---|---|---|---|---|
|
Number and Severity of Dose Limiting Toxicities (DLTs) Following Treatment With Escalating Doses of HPN424
|
6 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
Adverse Events
Fixed IV
Serious events: 41 serious events
Other events: 64 other events
Deaths: 37 deaths
1 Prime Step IV 36 ng/kg Target
Serious events: 3 serious events
Other events: 6 other events
Deaths: 3 deaths
1 Prime Step IV 225-300 ng/kg Target
Serious events: 7 serious events
Other events: 12 other events
Deaths: 9 deaths
2 Prime Step IV 300 ng/kg Target
Serious events: 8 serious events
Other events: 10 other events
Deaths: 5 deaths
2 Prime Step IV 450 ng/kg Target
Serious events: 5 serious events
Other events: 9 other events
Deaths: 3 deaths
Fixed SC
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Fixed IV
n=64 participants at risk
Fixed dose IV cohorts (1.3 to 150 ng/kg)
|
1 Prime Step IV 36 ng/kg Target
n=6 participants at risk
Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg)
|
1 Prime Step IV 225-300 ng/kg Target
n=12 participants at risk
Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
|
2 Prime Step IV 300 ng/kg Target
n=10 participants at risk
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
|
2 Prime Step IV 450 ng/kg Target
n=9 participants at risk
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
|
Fixed SC
n=3 participants at risk
Fixed subcutaneous dose 120 ng/kg
|
|---|---|---|---|---|---|---|
|
Immune system disorders
Cytokine release syndrome
|
26.6%
17/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
60.0%
6/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Immune system disorders
Type IV hypersensitivity reaction
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Aspartate aminotransferase increased
|
9.4%
6/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Alanine aminotransferase increased
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Transaminases increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood creatinine increased
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Electrocardiogram ST-T segment abnormal
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Liver function test increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal mass
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Pneumonia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Cellulitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Localised infection
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Mastoiditis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Sepsis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Urinary tract infection
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Seizure
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Cerebrovascular accident
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Brain oedema
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Cauda equina syndrome
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Syncope
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Atrial fibrillation
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Cardiac disorder
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Cardiac failure
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Myocardial infarction
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Constipation
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Pyrexia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Asthenia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Haematuria
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm prostate
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Anaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
Other adverse events
| Measure |
Fixed IV
n=64 participants at risk
Fixed dose IV cohorts (1.3 to 150 ng/kg)
|
1 Prime Step IV 36 ng/kg Target
n=6 participants at risk
Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg)
|
1 Prime Step IV 225-300 ng/kg Target
n=12 participants at risk
Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
|
2 Prime Step IV 300 ng/kg Target
n=10 participants at risk
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
|
2 Prime Step IV 450 ng/kg Target
n=9 participants at risk
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
|
Fixed SC
n=3 participants at risk
Fixed subcutaneous dose 120 ng/kg
|
|---|---|---|---|---|---|---|
|
General disorders
Fatigue
|
51.6%
33/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
4/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
8/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
60.0%
6/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
6/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
2/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Pyrexia
|
28.1%
18/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
5/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Chills
|
21.9%
14/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
44.4%
4/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Oedema peripheral
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Asthenia
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Malaise
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Injection site reaction
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
2/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Pain
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Chest discomfort
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Gait disturbance
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Infusion site extravasation
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Oedema
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Catheter site extravasation
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Chest pain
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Hernia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Injection site pain
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Injection site pruritus
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Peripheral swelling
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
General disorders
Vascular device occlusion
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Aspartate aminotransferase increased
|
34.4%
22/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
6/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
80.0%
8/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
100.0%
9/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Alanine aminotransferase increased
|
32.8%
21/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
58.3%
7/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
80.0%
8/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
88.9%
8/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood alkaline phosphatase increased
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
55.6%
5/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
2/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood bilirubin increased
|
12.5%
8/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Lymphocyte count decreased
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood creatinine increased
|
12.5%
8/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Weight decreased
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood lactate dehydrogenase increased
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Platelet count decreased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
44.4%
4/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
White blood cell count decreased
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood calcium decreased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood albumin decreased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood sodium decreased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
C-reactive protein increased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Neutrophil count decreased
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood glucose increased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Amylase increased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood phosphorus decreased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Haemoglobin decreased
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Lipase increased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Transaminases increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Haematocrit decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Liver function test increased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Mean cell haemoglobin concentration decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Protein total decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Red blood cell count decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Red cell distribution width increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Amylase decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood magnesium decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood phosphorus increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood pressure increased
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
International normalised ratio increased
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Platelet count increased
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Weight increased
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood albumin increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood alkaline phosphatase decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood chloride increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood creatinine decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood potassium decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Blood urea increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Carbon dioxide decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Cardiac murmur
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Electrocardiogram ST-T segment abnormal
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Electrocardiogram T wave abnormal
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Gamma-glutamyltransferase increased
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Mean cell haemoglobin decreased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
Neutrophil count increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Investigations
White blood cell count increased
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Nausea
|
35.9%
23/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
2/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
41.7%
5/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
44.4%
4/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Vomiting
|
21.9%
14/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
3/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
6/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Constipation
|
28.1%
18/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
44.4%
4/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Diarrhoea
|
12.5%
8/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
60.0%
6/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Abdominal pain
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Dyspepsia
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Toothache
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Eructation
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Dental caries
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Dry mouth
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Stomatitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Abdominal distension
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Anal incontinence
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Colitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Dysphagia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Gingival pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Lip blister
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Mouth ulceration
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Oral pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Proctalgia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Rectal prolapse
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Immune system disorders
Cytokine release syndrome
|
65.6%
42/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
3/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
83.3%
10/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
80.0%
8/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
100.0%
9/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
100.0%
3/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Immune system disorders
Type IV hypersensitivity reaction
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
20.3%
13/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
6/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
40.0%
4/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
55.6%
5/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
23.4%
15/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
14.1%
9/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis of jaw
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Metatarsalgia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Muscle atrophy
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
23.4%
15/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
4/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
9.4%
6/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
9.4%
6/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
2/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
2/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Dehydration
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Anaemia
|
35.9%
23/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
2/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
50.0%
5/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
66.7%
2/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Neutropenia
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Leukopenia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Cytopenia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Eosinophilia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Headache
|
15.6%
10/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
4/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Dizziness
|
15.6%
10/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Dysgeusia
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Paraesthesia
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Presyncope
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Seizure
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Cerebrovascular accident
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Cognitive disorder
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Neuropathy peripheral
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Syncope
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Taste disorder
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Tremor
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Brain oedema
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Cauda equina syndrome
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Dizziness postural
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Lethargy
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Nervous system disorders
Sciatica
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
14.1%
9/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
44.4%
4/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal mass
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
23.4%
15/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
2/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Fall
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Contusion
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Hyphaema
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Sunburn
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Urinary tract infection
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
2/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
COVID-19
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Cellulitis
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Sinusitis
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Pneumonia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Skin infection
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Tooth infection
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Candida infection
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Conjunctivitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Cystitis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Infective exacerbation of bronchiectasis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Localised infection
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Mastoiditis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Oral candidiasis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Phlebitis infective
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Sepsis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Sialoadenitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Stoma site cellulitis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Tooth abscess
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Upper respiratory tract infection
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Vascular disorders
Hypotension
|
14.1%
9/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Vascular disorders
Hypertension
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
30.0%
3/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Vascular disorders
Flushing
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Vascular disorders
Hot flush
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Insomnia
|
17.2%
11/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Confusional state
|
9.4%
6/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
25.0%
3/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Anxiety
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Depression
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Irritability
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Psychiatric disorders
Mood altered
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Tachycardia
|
10.9%
7/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
20.0%
2/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
3/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Atrial fibrillation
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Sinus bradycardia
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Cardiac failure
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Sinus tachycardia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Cardiac disorder
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Myocardial infarction
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
7.8%
5/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
6.2%
4/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
22.2%
2/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Skin and subcutaneous tissue disorders
Rash vesicular
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Haematuria
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
33.3%
1/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Acute kidney injury
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Nocturia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Urinary incontinence
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Pollakiuria
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Urinary tract discomfort
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Renal and urinary disorders
Urine odour abnormal
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Vision blurred
|
4.7%
3/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Cataract
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Eye pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Vitreous floaters
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Diplopia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Photophobia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Photopsia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Strabismus
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Eye disorders
Visual impairment
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
8.3%
1/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
10.0%
1/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm prostate
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Ear and labyrinth disorders
Ear pain
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Ear and labyrinth disorders
Hypoacusis
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Ear and labyrinth disorders
Tinnitus
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
16.7%
1/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Reproductive system and breast disorders
Testicular pain
|
3.1%
2/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Reproductive system and breast disorders
Gynaecomastia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
11.1%
1/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Reproductive system and breast disorders
Penile pain
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Endocrine disorders
Adrenal insufficiency
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
1.6%
1/64 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/6 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/12 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/10 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/9 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
0.00%
0/3 • From 28 days after they received their last dose of study drug to study completion, a median of approximately 313 days. Participants continued to receive doses until they progressed or stopped treatment for other reasons.
All events that occur or worsen in severity or frequency during or after the first HPN424 study drug administration through 28 days after the last dose of study drug. The primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as outlined in the final Statistical Analysis Plan.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place